The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
https://www.nature.com/articles/s41375-021-01266-6
the only way is up;)
https://www.youtube.com/watch?v=vjD3EVC1-zU
this ones for Tim & co
https://www.youtube.com/watch?v=BWf-eARnf6U
https://www.pharmaceutical-technology.com/features/lillys-indian-drugmakers-baricitinib-covid-19/
lets hope life's can be saved..
https://www.covid19treatmentguidelines.nih.gov/immunomodulators/kinase-inhibitors/#:~:text=February%2011%2C%202021-,Janus%20Kinase%20Inhibitors,interleukin%20%5BIL%5D%2D6).
https://www.crosstownnews.in/post/63804/who-warns-against-use-of-ivermectin-for-treatment-of-covid-19-.html
https://www.firstpost.com/health/goa-prescribes-ivermectin-for-all-above-18-to-fight-covid-19-as-experts-flag-concern-all-you-need-to-know-9611751.html
Ivermectin needs to be trialed 1st... India are desperate!
just re-read that article, hairs up on back of my neck, felt bit sick, then realised, this is now potentially the real deal!!!
No new competition, except the Chinese black market lol
Charlie and the chocolate factory, I've got my ticket;)
weeks now, not years fellow LTH's ;)
Its a massive market, WHO are desperate AIMOHO... Same old drugs....;) bring on the newbies...
https://www.greaterkashmir.com/news/front-page-2/who-to-restart-covid-drug-trial-with-focus-on-immune-responses/
GLALTH's
https://academic.oup.com/rheumatology/article/60/Supplement_2/ii3/6265525?rss=1
2 months my reckoning if all goes well, were rerate just with CTA 1801...
GLALTH's
Tim, check em out...
https://www.foresitecapital.com/
https://www.biospace.com/article/investors-launch-a-handful-of-new-biotechs/
...
Esker joins the Tyk2 race
https://www.evaluate.com/vantage/articles/interviews/esker-joins-tyk2-race
lets not get left behind Tim!...
https://www.edisongroup.com/edison-tv/sareum-holdings-edison-open-house-interview/
and we patiently wait...;)
so we have a private video...
invitation only...
sounds a bit raunchy to me..
https://www.edisongroup.com/company/sareum-holdings/2983/
There were only baricitinib and ruxolitinib in the included studies, therefore whether all JAK inhibitors provide the same benefits need further studies. There were only two RCT included in the analysis and only one RCT provided relatively large sample size. Consequently, more RCTs are still needed to further confirm these findings.
https://www.sciencedirect.com/science/article/pii/S2213398421000592
then we have our 1801, not long to wait..